Cutaneous melanoma in patients treated with tumour necrosis factor inhibitors: a retrospective series of 15 patients

Journal of the European Academy of Dermatology and Venereology

Volumn 28, Issue 11, 2014, Pages 1540-1544

  Chabbert, C ^a   Adamski, H ^a,h   Guillet, G ^b,h   Sassolas, B ^c,h   Misery, L ^c,h   Perrinaud, A ^d   Machet, L ^d,h   Quereux, G ^e,h   Esteve, E ^f,h   Solau Gervais, E ^b   Saraux, A ^c   Polard, E ^a   Lesimple, T ^g,h   Le Gall, F ^a   Dreno, B ^e,h   Dupuy, A ^a,h  

^a RENNES UNIVERSITY HOSPITAL   (France)

^b POITIERS UNIVERSITY HOSPITAL   (France)

^c BREST UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY HOSPITAL OF TOURS   (France)

^e NANTES UNIVERSITY HOSPITAL   (France)

^f Porte Madeleine Hospital of Orléans   (France)

^g Centre de Lutte Contre le Cancer Rennes   (France)

^h BIOtherapy and Research in DERMatology (BIORDERM) clinical research network of the French Grand Ouest regional area   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CUTANEOUS MELANOMA; DISEASE COURSE; DISEASE DURATION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; PUVA; RETROSPECTIVE STUDY; SEX RATIO; SKIN BIOPSY; TREATMENT DURATION; TUMOR DIAGNOSIS; VERY ELDERLY; YOUNG ADULT;

EID: 85006401240     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12347     Document Type: Article

References (21)

1. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumours. Proc Natl Acad Sci USA 1975; 72: 3666–3670.
2. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275–2285.
3. Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009; 68: 1136–1145.
4. Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf 2011; 20: 119–130.
5. Askling J. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005; 64: 1421–1426.
6. Setoguchi S, Solomon DH, Weinblatt ME et al. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 2757–2764.
7. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007; 56: 2886–2895.
8. Chakravarty EF, Michaud K, Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 2005; 32: 2130–2135.
9. Askling J, van Vollenhoven RF, Granath F et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? Arthritis Rheum 2009; 60: 3180–3189.
10. Raaschou P, Simard J, Holmqvist M, Askling J. Rheumatoid arthritis, anti-tumor necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. Br J Dermatol 2013; 346: f1939.
11. Lebas D, Staumont-Sallé D, Solau-Gervais E, Flipo R-M, Delaporte E. Manifestations cutanées observées au cours d'un traitement par anti-TNF alpha: 11 observations. Ann Dermatol Venereol 2007; 134: 337–342.
12. Khan I, Rahman L, McKenna DB. Primary cutaneous melanoma: a complication of infliximab treatment? Clin Exp Dermatol 2009; 34: 524–526.
13. Manganoni AM, Zane C, Pavoni L, Farisoglio C, Sereni E, Calzavara-Pinton P. Cutaneous melanoma in patients in treatment with biological therapy: review of the literature and case report. Dermatol Online J 2011; 17: 12.
14. Marasini B, Cozzaglio L, Belloli L, Massarotti M, Ughi N, Pedrazzoli P. Metastatic melanoma in a young woman treated with TNF-alpha inhibitor for psoriatic arthritis: a case report. Curr Drug Saf 2011; 6: 275–276.
15. Hacard F, Bens G, Maitre F, Le Bidre E, Esteve E. Mélanome survenant sur un site d'exérèse d'un naevus dysplasique au cours d'un traitement par étanercept. Ann Dermatol Venereol 2010; 137: 230–232.
16. Fulchiero GJ, Salvaggio H, Drabick JJ et al. Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies. J Am Acad Dermatol 2007; 56: S65–S67.
17. Kowalzick L, Eickenscheidt L, Komar M, Schaarschmidt E. Prolongierte Psoriasistherapie mit TNF-alpha-Antagonisten. Hautarzt 2009; 60: 655–657.
18. Katoulis AC, Kanelleas A, Zambacos G, Panayiotides I, Stavrianeas NG. Development of two primary malignant melanomas after treatment with adalimumab: a case report and review of the possible link between biological therapy with TNF-alpha antagonists and melanocytic proliferation. Dermatology 2010; 221: 9–12.
19. Institut National du Cancer. Epidémiologie du mélanome cutané en France Métropolitaine - Incidence et Mortalité 2013.http://lesdonnees.e-cancer.fr/les-fiches-de-synthese/1-types-cancer/14-melanome-cutane/44-epidemiologie-melanome-cutane-france-metropolitaine-incidence-mortalite.html (last accessed: 14 November 2013).
20. Matin RN, Mesher D, Proby CM et al. Melanoma in organ transplant recipients: clinicopathological features and outcome in 100 cases. Am J Transplant 2008; 8: 1891–1900.
21. Le Mire L, Hollowood K, Gray D, Bordea C, Wojnarowska F. Melanomas in renal transplant recipients. Br J Dermatol 2006; 154: 472–477.